Robert W. Baird Forecasts Strong Price Appreciation for argenex (NASDAQ:ARGX) Stock

argenex (NASDAQ:ARGX) had its target price increased by research analysts at Robert W. Baird from $858.00 to $867.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Robert W. Baird’s price objective suggests a potential upside of 13.05% from the stock’s previous close.

ARGX has been the topic of several other research reports. Morgan Stanley lifted their target price on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Guggenheim cut their price objective on shares of argenex from $1,160.00 to $1,120.00 and set a “buy” rating for the company in a report on Friday. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a report on Wednesday, January 21st. Citigroup cut their target price on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Wells Fargo & Company boosted their target price on argenex from $1,264.00 to $1,317.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $999.22.

argenex Price Performance

Shares of ARGX stock opened at $766.92 on Friday. argenex has a 1 year low of $510.05 and a 1 year high of $934.62. The firm has a fifty day moving average price of $826.36 and a 200-day moving average price of $811.97. The company has a market cap of $47.46 billion, a price-to-earnings ratio of 39.29, a PEG ratio of 0.67 and a beta of 0.37.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. argenex had a return on equity of 63.59% and a net margin of 30.42%.The business had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. Equities research analysts expect that argenex will post 3.13 EPS for the current year.

Institutional Trading of argenex

A number of hedge funds and other institutional investors have recently bought and sold shares of ARGX. M&T Bank Corp boosted its stake in shares of argenex by 20,977.7% during the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after purchasing an additional 774,916 shares during the period. Sands Capital Management LLC lifted its holdings in argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after buying an additional 340,245 shares in the last quarter. Invesco Ltd. boosted its position in argenex by 390.4% in the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after buying an additional 331,489 shares during the period. Wellington Management Group LLP grew its stake in argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after acquiring an additional 250,278 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.